WuXi STA, a subsidiary of WuXi AppTec, has announced its continuous manufacturing (CM) line for oral solids is in operation at its drug product site in Wuxi city, China.

The contract research, development, and manufacturing organisation (CRDMO)’s new line will provide customers worldwide with an oral drug development solution that enables higher yields and shorter timelines to market, the company noted.

The continuous manufacturing line is housed within an integrated formulation development and manufacturing campus that offers a comprehensive analytical platform for both oral and injectable formulations.

Dr Minzhang Chen, Co-CEO, WuXi AppTec and CEO, WuXi STA commented: “I am glad that our first oral solid dose drug product continuous manufacturing line has been launched in the Wuxi city site.”